Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19

INTRODUCTION: Remdesivir is the first agent with proven clinical efficacy against coronavirus disease 2019 (COVID-19); however, its benefit is associated with early use, and its efficacy has been poorly studied in patients with hemato-oncological diseases, who have an increased risk of a severe cour...

Descripción completa

Detalles Bibliográficos
Autores principales: Aksak-Wąs, Bogusz Jan, Chober, Daniel, Serwin, Karol, Scheibe, Kaja, Niścigorska-Olsen, Jolanta, Niedźwiedź, Anna, Dobrowolska, Monika, Żybul, Katarzyna, Kubacka, Marta, Zimoń, Agnieszka, Hołda, Ewa, Mieżyńska-Kurtycz, Joanna, Gryczman, Marta, Jamro, Grzegorz, Szakoła, Paweł, Parczewski, Miłosz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423106/
https://www.ncbi.nlm.nih.gov/pubmed/36046662
http://dx.doi.org/10.2147/JIR.S378347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423106/
https://www.ncbi.nlm.nih.gov/pubmed/36046662
http://dx.doi.org/10.2147/JIR.S378347

Ejemplares similares